• Home
• Slide Presentations
• Publications
• Study Information
• Diabetic Retinopathy
• Committee Members
• Contact
• Information for Journalists

Publications

The Lancet publication on the effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in Type 1 diabetes is available now at www.thelancet.com.

The Lancet publication on the effect of candesartan on progression and regression of retinopathy in Type 2 diabetes (DIRECT-Protect 2)  is available now at www.thelancet.com.

The baseline characteristics from the three studies in the DIRECT Programme are given in the baseline publication (The DIRECT Programme Study Group. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. JRAAS 2005;6:25–32).

Further details of the study designs of the three studies in the DIRECT Programme are given in the rationale and study design publication (The DIRECT Programme Study Group. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: rationale and study design. JRAAS 2002;3:255–261).